A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Cancer immunotherapy has advanced significantly, largely due to checkpoint blockade therapies targeting CTLA-4 and PD-1.
• Tumors evade immune responses by exploiting negative regulatory pathways, such as adenosine signaling via the A2a receptor in the tumor microenvironment.
• High adenosine concentrations in the tumor microenvironment contribute to immune suppression.

Purpose of the Study:

• To review the potential of blocking A2a receptor activation to enhance anti-tumor immunity.
• To present data on A2a receptor blockade's efficacy in combination with tumor vaccines, checkpoint blockade, and adoptive T cell therapy.
• To explore the complex role of adenosine signaling in immune responses, including instances where A2a receptor blockade may promote tumor progression.

Main Methods:

• Review of preclinical data and published studies on adenosine signaling and A2a receptor blockade in cancer.
• Analysis of the impact of A2a receptor antagonists on anti-tumor immune responses in various therapeutic settings.
• Examination of the complexities and nuances of adenosine-mediated immune regulation in the tumor microenvironment.

Main Results:

• A2a receptor blockade demonstrates potential to enhance the efficacy of cancer vaccines, checkpoint blockade, and adoptive T cell therapy in preclinical models.
• Adenosine signaling through the A2a receptor acts as a significant immunosuppressive mechanism within the tumor microenvironment.
• Certain conditions may lead to A2a receptor blockade paradoxically enhancing tumor progression, highlighting the complexity of this pathway.

Conclusions:

• A2a receptor antagonists represent a promising therapeutic strategy to augment anti-tumor immunity and enhance existing immunotherapies.
• Further elucidation of adenosine signaling complexities is crucial for optimizing the clinical application of A2a receptor antagonists.
• A2a receptor antagonists are being developed as novel immunotherapeutic agents, with some candidates already in late-stage clinical trials for other diseases.